Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Health Systems Can Lower Operational Costs and Reduce Environmental Impact with CareAdvantage from the Johnson & Johnson Medical Devices Companies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:32pm CEST

By a News Reporter-Staff News Editor at Ecology, Environment & Conservation -- With health systems focused on finding new ways to address their impact on the environment and reduce costs, CareAdvantage from the Johnson & Johnson Medical Devices Companies* now has a new Sustainability capability. Designed to help health systems achieve specific environmental, waste management, cost savings, and sustainable purchasing goals, this offering from the Johnson & Johnson Medical Devices Companies (JJMDC)* * draws on more than 25 years of sustainability commitments by the Johnson & Johnson Family of Companies, including its leadership in medical device reprocessing and its deep commitment to its Health for Humanity 2020 Goals.

There is a growing demand for sustainability strategies in the healthcare ecosystem among U.S. health system executives and operating room clinicians, according to insights from a new JJMDC survey, called the Voices for Value Insights Seriesii. The survey found that nine out of 10 clinicians (92%) and health system executives (88%) agree that sustainability provides long-term cost savings. The majority also agree that sustainability provides additional benefits, such as protecting the environment (76%), improving patient care (73%), and increasing the ability to manage risk and regulatory performance (68%). Nearly all (95%) believe that environmental sustainability contributes to the value of care delivered in their health system. The survey was conducted online between September 7 and 13, 2017 among 92 executives and clinicians at large U.S. health systems.

"Sustainability is critically important to Intermountain Healthcare, but recycling alone is not going to help us reach our goals," said Steve Bergstrom, Director of Sustainability at Intermountain Healthcare. "Our collaboration helps us reduce waste and operating room expenses through a more circular systems approach that is saving hundreds of thousands of dollars on medical device costs and diverting tens of thousands of pounds of Intermountain waste from landfills each year."

The CareAdvantage Sustainability capability enables best-in-class reprocessing across a broad spectrum of product categories, to include both JJMDC as well as non-JJMDC reprocessed single-use devices. It also includes practical tools and educational resources to help health systems create sustainability programs with financial and environmental benefits while implementing best practices for measuring and communicating the value of sustainability in healthcare.

The CareAdvantage Sustainability capability can also help purchasing and sustainability teams in healthcare delivery systems meet their Environmental Preferable Purchasing (EPP) goals. Specific expertise is designed to help healthcare delivery systems build a consistent approach to EPP assessments. In addition, through EARTHWARDS®, the Johnson & Johnson approach for encouraging the development of more sustainable products, health systems can access devices which have been designed with factors such as reducing materials, minimizing packaging, and reducing energy usage in mind.

"Drawing on our extensive experience in sustainability, we can provide health systems with a broad portfolio of sustainably sourced medical devices to help them meet their commitment to environmental stewardship efficiently and cost effectively," said Melinda Thiel, Vice President, Customer Marketing & Solutions at JJMDC. "This is just one element of how we approach customer needs, which starts with listening and leads to a holistic, tailored approach to help them reach their goals and deliver measurable results."

For more information about CareAdvantage and its capabilities, including Sustainability, visit www.careadvantagejjmdc.com. Join the discussion about value-based care on Voices for Value on LinkedIn.

Keywords for this news article include: Environment, Johnson & Johnson Medical Devices Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Science Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04:53p JOHNSON & JOHNSON : Fades With Profit, Forecast
03:08p JOHNSON & JOHNSON : Missouri appeals court throws out $72 million award in Johns..
02:21p JOHNSON & JOHNSON : Today's Research Reports on Stocks to Watch: Johnson & Johns..
02:03p UNITEDHEALTH : Agloan-Dow, S&P Reach New Highs
10:13a JOHNSON & JOHNSON : Briefly Briefly
08:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
07:21a JOHNSON & JOHNSON : Dow touches another record high point
06:02a JOHNSON & JOHNSON : Wins Reversal Of First St. Louis Talc-Cancer Verdict
02:45a JOHNSON & JOHNSON (NYSE : JNJ) reported earnings of $1.90 per share beating Wall..
10/17 JOHNSON & JOHNSON : Missouri appeals court tosses out $72 million dollar Johnson..
More news
News from SeekingAlpha
12:48p YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
12:00p Impact Of FASB's Pension Cost Accounting Rule Change
11:23a Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
10:24a JOHNSON & JOHNSON AT ALL-TIME HIGHS : Time To Sell Or To Buy?
08:56a Premarket analyst action - healthcare
Financials ($)
Sales 2017 75 884 M
EBIT 2017 22 951 M
Net income 2017 16 412 M
Debt 2017 17 928 M
Yield 2017 2,38%
P/E ratio 2017 23,49
P/E ratio 2018 18,83
EV / Sales 2017 5,22x
EV / Sales 2018 4,83x
Capitalization 378 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 140 $
Spread / Average Target -0,86%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423
AMGEN25.17%135 858